Meet The Professors: Pancreatic Cancer Edition, 2016 - Video 30Phase III MPACT study of weekly nab paclitaxel and gemcitabine versus gemcitabine alone: Use in patients with poor performance status
1:13 minutes.
TRANSCRIPTION:
DR BEKAII-SAAB: This study was straightforward, looking at a doublet with nab paclitaxel versus gemcitabine, which was the standard of care then, showing a survival advantage close to 2 months, which was statistically significant. And then the PFS was also improved in that study, again close to a couple of months, with a p-value. So PFS with the combination was about 5.5 months. I think the more interesting piece here, which is relevant for daily practice, especially for practices who still do use FOLFIRINOX in the better-performance patients, is that there is data with gemcitabine and nab paclitaxel in those with borderline performance status that still seem to have benefited from the combination versus gemcitabine. Those are the patients with KPS 70 or 80. The toxicities were mostly predictable. The combination of the 2 agents had more hematologic toxicities than the single agent. There were about one quarter of the patients that eventually received growth factor support, mostly to support the white count. |